Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immuno-plasma membrane inhibitor
- Development stage
- Preclinical
- Lead developer
- Voro Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intraperitoneal, Intramuscular, Intradermal, Intranodal, Intrasplenic
01
Overview
Immuno-plasma membrane inhibitor is a bispecific antibody being developed by Voro Therapeutics for the treatment of solid tumors. It is engineered using the company's proprietary PrimeBody™ platform, which creates tumor-activated therapies designed to improve the therapeutic index of potent immune-modulators. The drug's mechanism of action involves inhibiting tumor cell 'masking' mechanisms by targeting novel plasma membrane components that contribute to immune evasion. By unmasking these cells, the antibody aims to restore or enhance the immune system's ability to recognize and eliminate tumor cells. The program is currently in the Discovery/IND-enabling phase.
- Other names
- Immuno-plasma membrane inhibitor
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Immuno-plasma membrane inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuno-plasma membrane inhibitor.